Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CNR1 | P21554 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL10616820 | 0.94 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL12964960 | 0.89 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL10048248 | 0.87 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL16768875 | 0.86 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL3277527 | 0.86 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL10772550 | 0.86 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL34864 | 0.86 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL34863 | 0.86 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL16768884 | 0.86 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL10614607 | 0.86 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0112669-B1 | PHENETHYLAMINE DERIVATIVES AND INTERMEDIATES THEREFOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-29 | — | — | EP | claimed |
| US-4535186-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS; VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-08-13 | — | — | US | claimed |
| EP-0112669-A2 | Phenethylamine derivatives and intermediates therefor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-07-04 | — | — | EP | claimed |
| US-9784752-B2 | Venlafaxine assay | RANDOX LABORATORIES LIMITED (GB) | 2017-10-10 | — | — | US | disclosed |
| US-9784752-B2 | Venlafaxine assay | RANDOX LABORATORIES LIMITED (GB) | 2017-10-10 | — | — | US | disclosed |
| US-20140147859-A1 | Venlafaxine Assay | Randox Laboratories, Limited (GB) | 2014-05-29 | — | — | US | disclosed |
| US-7612210-B2 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1924249-A2 | TRANSDERMAL DRUG DELIVERY DEVICES CONTAINING O-DESMETHYL VENLAFAXINE (ODV) OR ITS SALTS | Wyeth a Corporation of the State of Delaware (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007030434-A2 | TRANSDERMAL DRUG DELIVERY DEVICES CONTAINING O-DESMETHYL VENLAFAXINE (ODV) OR ITS SALTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070053968-A1 | Transdermal drug delivery devices containing O-Desmethyl Venlafaxine (ODV) or its salts | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054964-A1 | Topical formulations containing O-Desmethyl Venlafaxine (ODV) or its salts | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-4761501-A | INTERMEDIATES FOR ANTIDEPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0112669-B1 | PHENETHYLAMINE DERIVATIVES AND INTERMEDIATES THEREFOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4611078-A | ANTIDEPRESSANT INTERMEDIATES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| US-4535186-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS; VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0112669-A2 | Phenethylamine derivatives and intermediates therefor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147859-A1 | Venlafaxine Assay | CYP2D6, SLC6A2, SLC6A4 | SLC6A2 2/4885SLC6A4 3/4885SLC6A3 6/4885 |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | MAP2K4, MAP2K1, MAP2K6 | SLC6A2 3642/4885SLC6A4 3291/4885SLC6A3 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.